Literature DB >> 16503828

Emerging pharmacological strategies in the fight against cocaine addiction.

Mehmet Sofuoglu1, Thomas R Kosten.   

Abstract

Cocaine addiction continues to be an important public health problem worldwide. At present, there are no proven pharmacotherapies for cocaine addiction. The studies reviewed here revealed a number of emerging targets for cocaine pharmacotherapy. First, disulfiram, a medication with dopaminergic effects, reduced cocaine use in a number of clinical trials. Second, GABA medications, tiagabine and topiramate, were found promising in clinical trials. Third, a beta-adrenergic blocker, propranolol, may be effective especially among cocaine-addicted individuals with high withdrawal severity. Fourth, treatment with a stimulant medication, modafinil, has reduced cocaine use. Last, a cocaine vaccine that slows entry of cocaine into the brain holds promise. These promising findings need to be further tested in controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503828     DOI: 10.1517/14728214.11.1.91

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  42 in total

Review 1.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

2.  Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis.

Authors:  Lina Yao; Peidong Fan; Maria Arolfo; Zhan Jiang; M Foster Olive; Jeff Zablocki; Hai-Ling Sun; Nancy Chu; Jeongrim Lee; Hee-Yong Kim; Kwan Leung; John Shryock; Brent Blackburn; Ivan Diamond
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

3.  The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.

Authors:  David A Nielsen; Sara C Hamon; Thomas R Kosten
Journal:  Psychiatr Genet       Date:  2013-12       Impact factor: 2.458

4.  Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and Galpha(i3) levels in nucleus accumbens.

Authors:  Marc N Potenza; Edward S Brodkin; Bao-Zhu Yang; Shari G Birnbaum; Eric J Nestler; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2008-01-23       Impact factor: 7.853

Review 5.  The neurobiology and genetics of impulse control disorders: relationships to drug addictions.

Authors:  Judson A Brewer; Marc N Potenza
Journal:  Biochem Pharmacol       Date:  2007-07-03       Impact factor: 5.858

Review 6.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

7.  Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands.

Authors:  William C Motel; Jason R Healy; Eddy Viard; Buddy Pouw; Kelly Martin; Rae R Matsumoto; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2013-10-15       Impact factor: 2.823

8.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

Review 9.  Molecular and genetic substrates linking stress and addiction.

Authors:  Lisa A Briand; Julie A Blendy
Journal:  Brain Res       Date:  2009-11-10       Impact factor: 3.252

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.